Mountain Valley MD (TSE:MVMD)
:MVMD
MVMD Stock Chart & Stats
C$0.02
<C$0.01(20.00%)
At close: 4:00 PM EST
C$0.02
<C$0.01(20.00%)
Day’s Range― - ―
52-Week RangeC$0.01 - C$0.08
Previous CloseN/A
Volume2.00K
Average Volume (3M)205.59K
Market Cap
C$28.19M
Enterprise ValueC$27.96M
Total Cash (Recent Filing)C$316.00K
Total Debt (Recent Filing)C$89.00K
Price to Earnings (P/E)―
Beta-0.73
Next Earnings
Jul 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding352,354,950
10 Day Avg. Volume152,980
30 Day Avg. Volume205,595
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)3.44
Price to Sales (P/S)177.77
P/FCF Ratio-2.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Minimal Leverage / Low DebtEffectively zero reported debt materially reduces bankruptcy and interest-rate risk for a small biotech. Low leverage preserves financial optionality for R&D or partnerships over months ahead, allowing management to prioritize development or licensing without heavy fixed financing costs.
Platform Delivery Technology FocusA platform aimed at improving delivery/stability of active ingredients provides scalable commercial pathways: multiple end-markets, licensing and partnerships. Structural demand for improved delivery systems supports long-term relevance if the platform demonstrates reproducible performance and regulatory progress.
Gross Profit Turned Positive In 2025Positive gross profit indicates that product/unit economics can cover direct production costs, a necessary precondition for sustainable margins. If management can control fixed operating expenses and scale revenue, positive gross margins improve the path to eventual operating profitability.
Bears Say
Persistent Cash Burn And Negative FCFConsistent negative operating and free cash flow (~-C$3.9M in 2025) signals ongoing cash consumption that cannot be self-funded. Over a multi-month horizon this increases reliance on external financing, which can dilute shareholders and constrain strategic options if capital markets tighten.
Eroding Equity / Shrinking Capital BaseA dramatic drop in shareholders' equity reduces the company’s buffer against losses and limits financial flexibility. With a thin capital base, any continued losses or financing missteps raise solvency and dilution risk, making multi-month planning and investment more precarious.
Very Small, Volatile Revenue BaseRevenue that is tiny and fell ~85% YoY demonstrates lack of stable commercial traction. A negligible, volatile top line undermines ability to absorb fixed costs, increases forecasting uncertainty, and makes scaling economics dependent on uncertain product or partner wins.
Mountain Valley MD News
MVMD FAQ
What was Mountain Valley MD’s price range in the past 12 months?
Mountain Valley MD lowest stock price was C$0.01 and its highest was C$0.08 in the past 12 months.
What is Mountain Valley MD’s market cap?
Mountain Valley MD’s market cap is C$28.19M.
When is Mountain Valley MD’s upcoming earnings report date?
Mountain Valley MD’s upcoming earnings report date is Jul 09, 2026 which is in 94 days.
How were Mountain Valley MD’s earnings last quarter?
Mountain Valley MD released its earnings results on Mar 02, 2026. The company reported -C$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.002.
Is Mountain Valley MD overvalued?
According to Wall Street analysts Mountain Valley MD’s price is currently Overvalued.
Does Mountain Valley MD pay dividends?
Mountain Valley MD does not currently pay dividends.
What is Mountain Valley MD’s EPS estimate?
Mountain Valley MD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mountain Valley MD have?
Mountain Valley MD has 352,354,950 shares outstanding.
What happened to Mountain Valley MD’s price movement after its last earnings report?
Mountain Valley MD reported an EPS of -C$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 33.333%.
Which hedge fund is a major shareholder of Mountain Valley MD?
Currently, no hedge funds are holding shares in TSE:MVMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mountain Valley MD
Mountain Valley MD Holdings Inc., through its subsidiary, Mountain Valley MD Inc., operates as a health and wellness company. The company engages in the implementation and licensing of its technologies to pharmaceutical, vaccine, and nutraceutical third parties. It offers Quicksome oral drug formulation and delivery technologies; Quicksol solubility formulation technology; and dose sparing adjuvant. In addition, the company is developing IM032 for the treatment of male beagle dogs for comparing intramuscular and subcutaneous dosing. Mountain Valley MD Holdings Inc. is headquartered in Concord, Canada.
Technical Analysis
Ayurcann Holdings Corp.
―
Revive Therapeutics
―
PharmaCielo
―
CanadaBis Capital
―
Lobe Sciences
―
Options Prices
Currently, No data available
---